Evolocumab (Repatha)

Indications

  • Hyperlipidemia: FDA-approved
    • Osler Trial

Pharmacology

  • Human PCSK9 Monoclonal Antibody: acts to

Metabolism

  • xxxx

Administration

  • Cost: $14,100/yr

Dose Adjustment

  • Hepatic:
  • Renal:

Adverse Effects

Other Adverse Effects

  • xxx
  • xxx
  • xxx

References

  • xxxx